Detalhe da pesquisa
1.
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
PLoS Pathog
; 11(7): e1005063, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26225566
2.
Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study.
Sex Transm Infect
; 93(1): 15-17, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27030607
3.
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
Clin Infect Dis
; 63(2): 268-80, 2016 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27090986
4.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
N Engl J Med
; 369(19): 1807-18, 2013 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24195548
5.
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
J Infect Dis
; 207 Suppl 2: S78-84, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23687293
6.
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
J Infect Dis
; 207(11): 1723-9, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23463709
7.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
J Antimicrob Chemother
; 67(8): 2020-8, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22532465
8.
Maraviroc for previously treated patients with R5 HIV-1 infection.
N Engl J Med
; 359(14): 1429-41, 2008 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-18832244
9.
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
J Antimicrob Chemother
; 66(8): 1878-85, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21652619
10.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
J Infect Dis
; 201(6): 803-13, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20151839
11.
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
J Antimicrob Chemother
; 65(11): 2450-4, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20801782
12.
Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study.
Nucl Med Commun
; 30(1): 41-7, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19306513
13.
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Clin Infect Dis
; 47(7): 969-78, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18764771
14.
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Antivir Ther
; 13(2): 297-306, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18505181
15.
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
AIDS Res Hum Retroviruses
; 24(3): 355-62, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18327983
16.
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
AIDS
; 21(6): 721-32, 2007 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17413693
17.
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
AIDS
; 21(12): 1555-9, 2007 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17630550
18.
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Clin Infect Dis
; 45(3): 381-90, 2007 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17599319
19.
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Basic Clin Pharmacol Toxicol
; 101(5): 339-44, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17910618
20.
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Lancet Infect Dis
; 17(3): 296-304, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27914856